# Title

 Food and Drugs. PART 882â€”NEUROLOGICAL DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 882


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'prior to', 'maximum', 'after', 'at least']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Duration    | ['18.0 month']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Condition   | ['unless', 'where', 'subject to', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Entities    | ['Thermal', 'Electric', 'Nerve', 'Neuropsychiatric', 'Depth', 'Cranial', 'Percutaneous', 'Electroconvulsive', 'Neurological', 'Percussor', 'Burr', 'Ultrasonic', 'Echoencephalograph', 'Software', 'Ventricular', 'Skull', 'Pneumatic', 'Biofeedback', 'Tremor', 'Microsurgical', 'Physiological', 'Embolization', 'Cutaneous', 'Electroencephalograph', 'Scalp', 'Brain', 'Shunt', 'Skullplate', 'Central', 'Alpha', 'Nystagmograph', 'Skin', 'Scope', 'B-scan', 'Cranioplasty', 'Leukotome', 'Cryogenic', 'Electroencephalogram', 'Food', 'Dura', 'Aversive', 'Ataxiagraph', 'Vibratory', 'Human', 'Methyl', 'Infrared', 'Aneurysm', 'Needle', 'Performance', 'Cortical', 'Lesion', 'Dowel', 'Manual', 'Stereotaxic', 'Carotid', 'Ocular', 'Appropriate', 'Rheoencephalograph', 'Nasopharyngeal', 'Galvanic', 'Nonpowered', 'Radiofrequency', 'Bite', 'Pinwheel', 'Rigidity', 'Neurovascular', 'Neurosurgical'] |
| Date        | ['2005-05-25', '1996-12-26', '1976-05-28', '1986-07-07', '1989-03-01', '2004-09-21', '1999-07-13', '1984-09-26']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                      |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------|
| after         | III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the        |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                 |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                 |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                         |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                         |
| after         | equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed    |
| before        | or declaring completed a PDP for the device before the device is commercially distributed unless it is                       |
| before        | an approval under section 515 of the act before  commercial distribution.                                                    |
| within        | or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of    |
| before        | must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce |
| after         | of concussion to determine cognitive function for patients after a potential concussive event where other diagnostic tools   |
| before        | with the Food and Drug Administration on or before September 21, 2004, for any ocular plethysmograph that                    |
| before        | with the Food and Drug Administration on or before September 21, 2004, for any ocular plethysmograph that                    |
| before        | approved PMA or declared completed PDP in effect before  being placed in commercial distribution.                            |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was                     |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was                     |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was                     |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was                     |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                   |
| after         | mechanism to disengage the tip of the instrument after penetrating the skull to prevent plunging of the                      |
| after         | have a clutch mechanism to disengage the tip after  penetrating the skull.                                                   |
| within        | mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part             |
| within        | to deliver the RF energy to the site within  the nervous system where a lesion is desired.                                   |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter                |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter                |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter                |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter                |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                   |
| at least      | without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on         |
| after         | leg and ankle of partially paralyzed patients (e.g., after stroke) to provide flexion of the foot and                        |
| before        | with the Food and Drug Administration on or before  September 26, 1984.                                                      |
| before        | cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on                        |
| before        | cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on                        |
| before        | cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on                        |
| before        | cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on                        |
| before        | with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve                |
| before        | with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve                |
| before        | with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve                |
| before        | with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve                |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                   |
| within        | an implanted receiver with electrodes that are placed within a patient's brain and an external transmitter for               |
| before        | with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator     |
| before        | with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator     |
| before        | with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator     |
| before        | with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator     |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                   |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord                           |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord                           |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord                           |
| before        | with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord                           |
| before        | PMA or a declared completed PDP in effect before  being placed in commercial distribution.                                   |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator                  |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator                  |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator                  |
| before        | with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator                  |
| before        | approved PMA or declared completed PDP in effect before  being placed in commercial distribution.                            |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | ),  maximum  average current (mA),                                                                                           |
| maximum       | ),  maximum  average current (mA),                                                                                           |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | parameters of the device, including waveform, output modes, maximum output voltage and current (with 500, 2,000, and         |
| maximum       | ),  maximum  average current (mA),                                                                                           |
| maximum       | ),  maximum  average current (mA),                                                                                           |
| maximum       | specifications of the device (i.e., total charge delivered, maximum  instantaneous output current,                           |
| maximum       | specifications of the device (i.e., total charge delivered, maximum  instantaneous output current,                           |
| maximum       | (ii) Technical parameters of the device ( maximum  output voltage (instantaneous),                                           |
| prior to      | (iv) The anticipated number of device uses  prior to  failure.                                                               |
| prior to      | is only applicable to human dura mater recovered prior to  May 25, 2005.                                                     |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                               |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 18.0 month | A cranial orthosis is a device that is intended for medical purposes to apply pressure to prominent regions of an infant's cranium in order to improve cranial symmetry and/or shape in infants from 3 to 18 months of age, with moderate to severe nonsynostotic positional plagiocephaly, including infants with plagiocephalic-, brachycephalic-, and scaphocephalic-shaped heads. |


## Condition

| Condition     | Context                                                                                                                  |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------|
| subject to    | of every device that is, or will be, subject to  the regulation.                                                         |
| unless        | Regulations are to chapter I of title 21, unless  otherwise noted.                                                       |
| unless        | date shown in the regulation classifying the device unless the manufacturer has an approval under section 515            |
| unless        | Accordingly,  unless an effective date of the requirement for premarket                                                  |
| unless        | the device before the device is commercially distributed unless  it is reclassified.                                     |
| where         | or the device is intended for lay use where the former intended use was by health care                                   |
| when          | into interstate commerce for commercial distribution the device when : (a) The device is intended for a                  |
| when          | measuring the amount of swaying of the body when the patient is standing erect and with eyes                             |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| where         | and instructions for reprocessing of any reusable components. where                                                      |
| when          | integrate the device output into their diagnostic pathway when the device is unable to provide a classification          |
| if            | The summary of testing must include the following,  if available: Any expected or observed adverse events and            |
| where         | function for patients after a potential concussive event where other diagnostic tools are available and does not         |
| provided that | (2) Clinical performance data must be  provided that demonstrates how the device functions as an interpretation          |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter, subject to  the limitations in &#167;&#8201;882.9.                                |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| where         | energy to the site within the nervous system where  a lesion is desired.                                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;882.9.                                                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;882.9.                                 |
| when          | subpart E of part 807 of this chapter when it is a prescription battery powered device that                              |
| subject to    | relaxation training and muscle reeducation and prescription use, subject to  &#167;&#8201;882.9.                         |
| where         | to monitor the tissue temperature at the site where a lesion (tissue destruction) is to be made                          |
| when          | a lesion (tissue destruction) is to be made when a surgeon uses a radiofrequency (RF) lesion generator                   |
| if            | users to contact the device manufacturer and MedWatch if  they experience any adverse events with this device.           |
| if            | the device contains software or firmware, appropriate ver if ication, validation, and hazard analysis must be performed. |
| if            | (5) Labeling must include:                                                                                               |
|               |               (i) Spec if ic information pertinent to use of the device                                                  |
| if            | (5) Labeling must include:                                                                                               |
|               |               (i) Spec if ic information pertinent to use of the device                                                  |
| when          | MedWatch in case they experience any adverse events when  using this device.                                             |
| where         | to cover bone edges of craniectomy sites (sites where the skull has been cut) to prevent the                             |


## Entities

| Entities              | Context                                                                                                                                |
|:----------------------|:---------------------------------------------------------------------------------------------------------------------------------------|
| Food                  | Food  and Drugs.                                                                                                                       |
| Scope                 | Scope .                                                                                                                                |
| Rigidity              | Rigidity  analyzer.                                                                                                                    |
| Ataxiagraph           | Ataxiagraph .                                                                                                                          |
| Echoencephalograph    | Echoencephalograph .                                                                                                                   |
| B-scan                | echoencephalograph is an ultrasonic scanning device (including A-scan, B-scan , and doppler systems) that uses noninvasive transducers |
| Cortical              | Cortical  electrode.                                                                                                                   |
| Cutaneous             | Cutaneous  electrode.                                                                                                                  |
| Depth                 | Depth  electrode.                                                                                                                      |
| Nasopharyngeal        | Nasopharyngeal  electrode.                                                                                                             |
| Needle                | Needle  electrode.                                                                                                                     |
| Electroencephalograph | Electroencephalograph .                                                                                                                |
| Electroencephalograph | Electroencephalograph  electrode/lead tester.                                                                                          |
| Electroencephalogram  | Electroencephalogram  (EEG) signal spectrum analyzer.                                                                                  |
| Electroencephalograph | Electroencephalograph  test signal generator.                                                                                          |
| Neuropsychiatric      | Neuropsychiatric  interpretive electroencephalograph assessment aid.                                                                   |
| Appropriate           | Appropriate  verification, validation, and hazard analysis must be performed.                                                          |
| Appropriate           | Appropriate software verification, validation, and hazard analysis must be                                                             |
| Performance           | Performance measures must demonstrate device performance characteristics per the                                                       |
| Performance           | Performance measurements must include sensitivity, specificity, positive predictive value,                                             |
| Brain                 | Brain  injury adjunctive interpretive electroencephalograph assessment aid.                                                            |
| Appropriate           | Appropriate  verification, validation, and hazard analysis must be performed.                                                          |
| Appropriate           | Appropriate software verification, validation, and hazard analysis must be                                                             |
| Performance           | Performance measures must demonstrate device performance characteristics per the                                                       |
| Performance           | Performance measurements must include sensitivity, specificity, positive predictive value                                              |
| Nystagmograph         | Nystagmograph .                                                                                                                        |
| Appropriate           | Appropriate  verification, validation, and hazard analysis must be performed.                                                          |
| Appropriate           | Appropriate software verification, validation, and hazard analysis must be                                                             |
| Software              | Software  verification, validation, and hazard analysis must be performed.                                                             |
| Neurological          | Neurological  endoscope.                                                                                                               |
| Galvanic              | Galvanic  skin response measurement device.                                                                                            |
| Nerve                 | Nerve  conduction velocity measurement device.                                                                                         |
| Skin                  | Skin  potential measurement device.                                                                                                    |
| Appropriate           | Appropriate  verification, validation, and hazard analysis must be performed.                                                          |
| Appropriate           | Appropriate software verification, validation, and hazard analysis must be                                                             |
| Performance           | Performance measurements must include positive percent agreement and false                                                             |
| Alpha                 | Alpha  monitor.                                                                                                                        |
| Cranial               | Cranial  motion measurement device.                                                                                                    |
| Percussor             | Percussor .                                                                                                                            |
| Pinwheel              | Pinwheel .                                                                                                                             |
| Ocular                | Ocular  plethysmograph.                                                                                                                |
| Rheoencephalograph    | Rheoencephalograph .                                                                                                                   |
| Physiological         | Physiological  signal amplifier.                                                                                                       |
| Physiological         | Physiological  signal conditioner.                                                                                                     |
| Electroencephalogram  | Electroencephalogram  (EEG) telemetry system.                                                                                          |
| Ultrasonic            | Ultrasonic  scanner calibration test block.                                                                                            |
| Infrared              | Near  Infrared  (NIR) Brain Hematoma Detector.                                                                                         |
| Infrared              | A Near  Infrared (NIR) Brain Hematoma Detector is a noninvasive device                                                                 |
| Tremor                | Tremor  transducer.                                                                                                                    |
| Skull                 | Skull  plate anvil.                                                                                                                    |
| Ventricular           | Ventricular  cannula.                                                                                                                  |
| Ventricular           | Ventricular  catheter.                                                                                                                 |
| Neurosurgical         | Neurosurgical  chair.                                                                                                                  |
| Scalp                 | Scalp  clip.                                                                                                                           |
| Aneurysm              | Aneurysm  clip applier.                                                                                                                |
| Cryogenic             | Cryogenic  surgical device.                                                                                                            |
| Dowel                 | Dowel  cutting instrument.                                                                                                             |
| Manual                | Manual cranial drills, burrs, trephines, and their accessories (a)                                                                     |
| Manual                | Manual cranial drills, burrs, trephines, and their accessories are                                                                     |
| Cranial               | Cranial  drill handpiece (brace).                                                                                                      |
| Electric              | Electric  cranial drill motor.                                                                                                         |
| Pneumatic             | Pneumatic  cranial drill motor.                                                                                                        |
| Radiofrequency        | Radiofrequency  lesion generator.                                                                                                      |
| Neurosurgical         | Neurosurgical  headrests.                                                                                                              |
| Neurosurgical         | Neurosurgical  head holder (skull clamp).                                                                                              |
| Cranioplasty          | Cranioplasty  material forming instrument.                                                                                             |
| Microsurgical         | Microsurgical  instrument.                                                                                                             |
| Nonpowered            | Nonpowered  neurosurgical instrument.                                                                                                  |
| Shunt                 | Shunt  system implantation instrument.                                                                                                 |
| Stereotaxic           | Stereotaxic  instrument.                                                                                                               |
| Leukotome             | Leukotome .                                                                                                                            |
| Neurosurgical         | Neurosurgical  suture needle.                                                                                                          |
| Neurosurgical         | Neurosurgical  paddie.                                                                                                                 |
| Radiofrequency        | Radiofrequency  lesion probe.                                                                                                          |
| Skull                 | Skull  punch.                                                                                                                          |
| Manual                | Manual  rongeur.                                                                                                                       |
| Skullplate            | Skullplate  screwdriver.                                                                                                               |
| Methyl                | Methyl  methacrylate for aneurysmorrhaphy.                                                                                             |
| Methyl                | Methyl methacrylate for aneurysmorrhaphy (repair of aneurysms, which are                                                               |
| Biofeedback           | Biofeedback  device.                                                                                                                   |
| Bite                  | Bite  block.                                                                                                                           |
| Carotid               | Carotid  artery clamp.                                                                                                                 |
| Aneurysm              | Aneurysm  clip.                                                                                                                        |
| Aversive              | Aversive  conditioning device.                                                                                                         |
| Burr                  | Burr  hole cover.                                                                                                                      |
| Nerve                 | Nerve  cuff.                                                                                                                           |
| Methyl                | Methyl  methacrylate for cranioplasty.                                                                                                 |
| Methyl                | Methyl methacrylate for cranioplasty (skull repair) is a self-curing                                                                   |
| Cranioplasty          | Cranioplasty  plate fastener.                                                                                                          |
| Lesion                | Lesion  temperature monitor.                                                                                                           |
| Central               | Central  nervous system fluid shunt and components.                                                                                    |
| Thermal               | Thermal  system for insomnia.                                                                                                          |
| Cranial               | Cranial  electrotherapy stimulator.                                                                                                    |
| Software              | Software  verification, validation, and hazard analysis must be performed.                                                             |
| Software              | Software documentation must demonstrate that the device effectively implements                                                         |
| Vibratory             | Vibratory  counter-stimulation device.                                                                                                 |
| Percutaneous          | Percutaneous  nerve stimulator for substance use disorders.                                                                            |
| Dura                  | Dura  substitute.                                                                                                                      |
| Electroconvulsive     | Electroconvulsive  therapy device.                                                                                                     |
| Neurovascular         | Neurovascular  embolization device.                                                                                                    |
| Embolization          | Embolization devices used in other vascular applications are also                                                                      |
| Skull                 | Skull  tongs for traction.                                                                                                             |
| Skull                 | Skull tongs for traction is an instrument used to                                                                                      |
| Cranial               | Cranial  orthosis.                                                                                                                     |
| Human                 | Human  dura mater.                                                                                                                     |
| Human                 | Human dura mater is human pachymeninx tissue intended to                                                                               |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified.                  |
| 1976-05-28 | Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                                                        |
| 2004-09-21 | A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 21, 2004, for any ocular plethysmograph that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                                                       |
| 1976-05-28 | A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 21, 2004, for any ocular plethysmograph that was in commercial distribution before May 28, 1976.                                                                                                                                                                                                                                                       |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rheoencephalograph that was in commercial distribution before May 28, 1976.                                                                                   |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rheoencephalograph that was in commercial distribution before May 28, 1976.                                                                                   |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rheoencephalograph that was in commercial distribution before May 28, 1976.                                                                                   |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any rheoencephalograph that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a rheoencephalograph that was in commercial distribution before May 28, 1976.                                                                                   |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an intravascular occluding catheter that was in commercial distribution before May 28, 1976.                                                      |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an intravascular occluding catheter that was in commercial distribution before May 28, 1976.                                                      |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an intravascular occluding catheter that was in commercial distribution before May 28, 1976.                                                      |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any intravascular occluding catheter that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an intravascular occluding catheter that was in commercial distribution before May 28, 1976.                                                      |
| 1984-09-26 | A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 26, 1984.                                                                                                                                                                                                                                                                                                                                              |
| 1976-05-28 | Any implanted cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on or before September 26, 1984 been found by FDA to be substantially equivalent to an implanted cerebellar stimulator that was in commercial distribution before May 28, 1976 shall have an approved PMA or declared completed PDP in effect before beginning commercial distribution.                                                                           |
| 1984-09-26 | Any implanted cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on or before September 26, 1984 been found by FDA to be substantially equivalent to an implanted cerebellar stimulator that was in commercial distribution before May 28, 1976 shall have an approved PMA or declared completed PDP in effect before beginning commercial distribution.                                                                           |
| 1976-05-28 | Any implanted cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on or before September 26, 1984 been found by FDA to be substantially equivalent to an implanted cerebellar stimulator that was in commercial distribution before May 28, 1976 shall have an approved PMA or declared completed PDP in effect before beginning commercial distribution.                                                                           |
| 1986-07-07 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976, or that has on or before July 7, 1986 been found to be substantially equivalent to an implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976.                                 |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976, or that has on or before July 7, 1986 been found to be substantially equivalent to an implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976.                                 |
| 1986-07-07 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976, or that has on or before July 7, 1986 been found to be substantially equivalent to an implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976.                                 |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 7, 1986 for any implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976, or that has on or before July 7, 1986 been found to be substantially equivalent to an implanted diaphragmatic/phrenic nerve stimulator that was in commercial distribution before May 28, 1976.                                 |
| 1989-03-01 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976, or that has on or before March 1, 1989, been found to be substantially equivalent to an implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976. |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976, or that has on or before March 1, 1989, been found to be substantially equivalent to an implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976. |
| 1989-03-01 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976, or that has on or before March 1, 1989, been found to be substantially equivalent to an implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976. |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 1, 1989, for any implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976, or that has on or before March 1, 1989, been found to be substantially equivalent to an implanted intracerebral/subcortical stimulator for pain relief that was in commercial distribution before May 28, 1976. |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976.        |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976.        |
| 1996-12-26 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976.        |
| 1976-05-28 | A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an implanted spinal cord stimulator for bladder evacuation that was in commercial distribution before May 28, 1976.        |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976.   |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976.   |
| 1999-07-13 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976.   |
| 1976-05-28 | A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an implanted neuromuscular stimulator that was in commercial distribution before May 28, 1976.   |
| 2005-05-25 | The classification set forth in this section is only applicable to human dura mater recovered prior to May 25, 2005.                                                                                                                                                                                                                                                                                                                                                               |


